Prolonged urocortin 2 administration in experimental heart failure: Sustained hemodynamic, endocrine, and renal effects

Hypertension

Volumn 57, Issue 6, 2011, Pages 1136-1144

  Rademaker, Miriam T ^a   Charles, Christopher J ^a   Ellmers, Leigh J ^a   Lewis, Lynley K ^a   Nicholls, M Gary ^a   Richards, A Mark ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

heart failure; hemodynamics; hormones; renal function; urocortin 2

Indexed keywords

ADRENALIN; ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; CREATININE; ENDOTHELIN 1; HYDROCORTISONE; NORADRENALIN; POTASSIUM; SODIUM; UROCORTIN II; VASOPRESSIN;

ADRENALIN BLOOD LEVEL; ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FOOD INTAKE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT ATRIUM PRESSURE; HEART MUSCLE CONTRACTILITY; HYDROCORTISONE BLOOD LEVEL; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; SHEEP; SODIUM URINE LEVEL; VASCULAR RESISTANCE; VASOPRESSIN BLOOD LEVEL;

ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; CREATININE; ENDOCRINE SYSTEM; ENDOTHELIN-1; FEMALE; HEART; HEART FAILURE; HEMODYNAMICS; INFUSIONS, INTRAVENOUS; KIDNEY; MICE; OLIGOPEPTIDES; RENIN; SHEEP; SODIUM; TIME FACTORS; UROCORTINS; VASCULAR RESISTANCE; VASOPRESSINS;

EID: 79956337356     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.173203     Document Type: Article

References (32)

1. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 1995;378:287-292.
2. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med. 2001;7:605-611. (Pubitemid 32448329)
3. Wiley KE, Davenport AP. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol. 2004;143:508-514. (Pubitemid 39452218)
4. Hashimoto K, Makino S, Asaba K, Nishiyama. Physiological roles of corticotropin-releasing hormone receptor type 2. Endocrine J. 2001; 48:1-9. (Pubitemid 32230379)
5. Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Nat Acad Sci USA. 2004;101:3697-3702. (Pubitemid 38338257)
6. Rademaker MT, Charles CJ, Espiner EA, Fisher S, Frampton CM, Kirkpatrick CM, Lainchbury JG, Nicholls MG, Richards AM, Vale WW. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol. 2002;40:1495-1505. (Pubitemid 35192877)
7. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation. 2005;112: 3624-3632. (Pubitemid 43739541)
8. Davis ME, Pemberton CJ, Yandle TG, Lainchbury JG, Rademaker MT, Nicholls MG, Frampton CM, Richards AM. Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin Sci. 2005;109: 381-388. (Pubitemid 41445245)
9. Davis ME, Pemberton CJ, Yandle TG, Fisher SS, Lainchbury JG, Frampton CM, Rademaker MT, Richards AM. Urocortin 2 infusion in human heart failure. Eur Heart J. 2007;28:2589-2597. (Pubitemid 350071510)
10. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM. Endogenous urocortins reduce vascular tone and renin-aldosterone/ endothelin activity in experimental heart failure. Eur Heart J. 2005;26:2046-2054. (Pubitemid 41435717)
11. Moral MA. Tomillero A. Gateways to clinical trials. Methods Findings Exp Clin Pharmacol. 2008;30:149-171. (Pubitemid 351738275)
12. Fitzpatrick MA, Nicholls MG, Espiner EA, Ikram H, Bagshaw P, Yandle TG. Neurohumoral changes during the onset and offset of ovine heart failure: Role of ANP. Am J Physiol. 1989;256:H1052-H1059.
13. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Nicholls MG, Richards AM. Natriuretic peptide responses to acute and chronic pacing in sheep. Am J Physiol. 1996;270:H594-H602.
14. Rademaker MT, Charles CJ, Richards AM. Urocortin 1 administration from the onset of rapid left ventricular pacing represses progression to overt heart failure. Am J Physiol. 2007;293:H1536-H1544. (Pubitemid 47367198)
15. Dieterle T, Meili-Butz S, Buhler K, Morandi C, Dietlinde J, Buser PT, Rivier J, Vale WW, Peterson KL, Brink M. Immediate and sustained blood pressure lowering by urocortin 2: a novel approach to antihypertensive therapy? Hypertension. 2009;53:739-744.
16. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM. Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J. 2005;26:2055-2062. (Pubitemid 41435727)
17. Charles CJ, Jardine DL, Rademaker MT, Richards AM. Urocortin 2 induces potent long-lasting inhibition of cardiac sympathetic drive despite baroreflex activation in conscious sheep. J Endocrinol. 2010;204: 181-189.
18. Abdelrahman AM, Lin Lim S, Pang CC. Influence of urocortin and corticotropin releasing factor on venous tone in conscious rats. Eur J Pharmacol. 2005;510:107-111. (Pubitemid 40312395)
19. Yang C, Liu X, Li S. Effect of long-term treatment with urocortin on the activity of somatic angiotensin-converting enzyme in spontaneously hypertensive rats. Can J Physiol Pharmacol. 2010;88:168-176.
20. Davis JO, Freeman RH. Mechanisms regulating renin release. Physiol Rev. 1976;56:1-56.
21. Rademaker MT, Charles CJ, Nicholls MG, Richards AM. Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure. Clin Sci. 2008;114:635-642. (Pubitemid 351589062)
22. Ferrario CM. Angiotension-(1-7) and antihypertensive mechanisms. J Nephrol. 1998;11:278-283.
23. Robertson GL. Physiology of vasopressin, oxytocin, and thirst. In: Principles and Practice of Endocrinology and Metabolism. 3rd ed. Kenneth Becker ed. Lippincott Williams & Wilkins: Philadelphia, PA. 2001; 276-285.
24. Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci. 2005;108:23-36. (Pubitemid 40052282)
25. Ikeda K, Tojo K, Otsubo C, Udagawa T, Hosoya T, Tajima N, Nakao K, Kawamura M. Effects of urocortin II on neonatal rat cardiac myocytes and non-myocytes. Peptides. 2005;26:2473-2481. (Pubitemid 41676719)
26. Gardiner SM, March JE, Kemp PA, Davenport AP, Wiley KE, Bennett T. Regional hemodynamic actions of selective corticotropin-releasing factor type 2 receptor ligands in conscious rats. J Pharmacol Exp Therapeut. 2005;312:53-60. (Pubitemid 40096452)
27. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, Lee KF. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nature Genetics. 2000;24:410-414. (Pubitemid 30187443)
28. Cohen ML, Bloomquist W, Li D, Iyengar S. Effect of acute and subchronic subcutaneous urocortin on blood pressure and food consumption in ob/ob mice. General Pharmacol. 2000;34:371-377. (Pubitemid 32718752)
29. Ohata H, Shibasaki T. Effects of urocortin 2 and 3 on motor activity and food intake in rats. Peptides. 2004;25:1703-1709. (Pubitemid 39346212)
30. Hashimoto K, Nishiyama M, Tanaka Y, Noguchi T, Asaba K, Hossein PN, Nishioka T, Makino S. Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system. Peptides. 2004;25:1711-1721. (Pubitemid 39346213)
31. Kastin AJ, Akerstrom V. Differential interactions of urocortin/ corticotropin-releasing hormone peptides with the blood-brain barrier. Neuroendocrinol. 2002;75:367-374. (Pubitemid 34639040)
32. Pan W, Kastin AJ. Urocortin and the brain. Progress in Neurobiol. 2008;84:148-156.